HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price target would suggest a potential upside of 332.90% from the company's previous close.

SGMO has been the topic of several other reports. Barclays increased their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. Truist Financial raised Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 price target for the company in a report on Friday, December 13th. Finally, StockNews.com raised Sangamo Therapeutics from a "hold" rating to a "buy" rating in a report on Monday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Sangamo Therapeutics Stock Down 1.7 %

Shares of NASDAQ SGMO traded down $0.04 during midday trading on Thursday, hitting $2.31. 21,162,092 shares of the company's stock were exchanged, compared to its average volume of 6,913,354. The firm has a market capitalization of $481.97 million, a PE ratio of -3.08 and a beta of 1.15. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The company's 50 day moving average price is $1.91 and its 200 day moving average price is $1.11.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period in the previous year, the company earned ($0.34) earnings per share. On average, equities research analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Meritage Portfolio Management increased its position in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 6,740 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 38,850 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Sangamo Therapeutics by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company's stock valued at $956,000 after buying an additional 57,125 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 64,981 shares during the period. Finally, Golden State Equity Partners boosted its position in shares of Sangamo Therapeutics by 35.2% during the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company's stock worth $231,000 after acquiring an additional 69,368 shares in the last quarter. 56.93% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.